Imugene Limited (ASX: IMU) delivered a milestone quarter as it continued advancing the clinical development of its lead allogeneic CAR-T therapy, azer-cel. The company reported encouraging treatment responses from its ongoing Phase 1b study, including complete and partial responses in patients with advanced B-cell cancers who had previously exhausted available treatment options. Regulatory momentum also improved after azer-cel received additional U.S. Food and Drug Administration Fast Track Designations, while updated clinical results presented at the ASCO 2026 Annual Meeting demonstrated strong efficacy across several blood cancer indications. These developments further reinforce the therapy's potential as an off-the-shelf treatment for patients with significant unmet medical needs.
Alongside its clinical progress, Imugene enhanced its financial flexibility by completing a capital raising and securing commitments for a further AU$11.12 million placement to fund upcoming clinical milestones and business development activities. The company also sharpened its strategic focus by concentrating resources on azer-cel, implementing cost-saving initiatives across its research programs, strengthening its board with new independent directors, and beginning the search for a new Chief Executive Officer following the resignation of Leslie Chong.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Imugene Strengthens Clinical Momentum
Imugene Limited (ASX: IMU) delivered a milestone quarter as it continued advancing the clinical development of its lead allogeneic CAR-T therapy, azer-cel. The company reported encouraging treatment responses from its ongoing Phase 1b study, including complete and partial responses in patients with advanced B-cell cancers who had previously exhausted available treatment options. Regulatory momentum also improved after azer-cel received additional U.S. Food and Drug Administration Fast Track Designations, while updated clinical results presented at the ASCO 2026 Annual Meeting demonstrated strong efficacy across several blood cancer indications. These developments further reinforce the therapy's potential as an off-the-shelf treatment for patients with significant unmet medical needs.
Alongside its clinical progress, Imugene enhanced its financial flexibility by completing a capital raising and securing commitments for a further AU$11.12 million placement to fund upcoming clinical milestones and business development activities. The company also sharpened its strategic focus by concentrating resources on azer-cel, implementing cost-saving initiatives across its research programs, strengthening its board with new independent directors, and beginning the search for a new Chief Executive Officer following the resignation of Leslie Chong.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au